View source for CR:DOI:c95f54188db7f1d73abce2f0fe54c15c

{{#scite:
 |reference=maertens2021po
 |type=journal-article
 |title=Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
 |author=Johan A Maertens;Galia Rahav;Dong-Gun Lee;Alfredo Ponce-de-León;Isabel Cristina Ramírez Sánchez;Nikolay Klimko;Anne Sonet;Shariq Haider;Juan Diego Vélez;Issam Raad;Liang-Piu Koh;Meinolf Karthaus;Jianying Zhou;Ronen Ben-Ami;Mary R Motyl;Seongah Han;Anjana Grandhi;Hetty Waskin|+sep=;
 |journal=The Lancet
 |publisher=Elsevier BV
 |year=2021
 |volume=397
 |issue=10273
 |pages=499-509
 |doi=10.1016/s0140-6736(21)00219-1
 |issn=0140-6736
 |retrieved-from=https://dx.doi.org/
 |retrieved-on=2024-10-01
 |@show=true
}}